In part 5 of this Exclusive Interview, Dr. Jim McDermott explains DapaCare, the umbrella term that covers AstraZeneca’s clinical program with Farxiga (dapagliflozin) in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Jim McDermott, PhD, is the Vice President of U.S. Medical Affairs, Diabetes at AstraZeneca.
Transcript of this video segment:
Freed: Well it was easy in 1950… if you had type 2 diabetes there was no decision, you were just put on sulfonylurea. Today, it difficult. It’s better, no question. But it is more difficult for the physician to take that multiple drug combination and to see which one is going to work best because everybody’s different. Now they’re working on gene therapy where eventually, by doing some DNA and once we know your DNA, we’ll know what drug is going to be suitable for you and that will take the decision away and will make the physicians’ job much easier.
McDermott: Well it will definitely make the decision easier.
Freed: As of today, I think it makes it a little bit more difficult with all these options available. But we’re seeing a drop totally across the country or across the globe of A1C, so we’re learning that it takes time. So maybe you can talk a little bit to us about DapaCare – AstraZeneca’s new clinical program.
McDermott: Yes, DapaCare is a term that we use, it’s an umbrella over our clinical program with Farxiga, dapagliflozin. This is a program where we have several studies, DECLARE our CV outcomes trial as part of DapaCare. We also have a CKD study looking at Farxiga in patients with chronic kidney disease and this is both patients with diabetes and patients who do not have diabetes. We also have, within the DapaCare, a large study that we just kicked off for heart failure. And again, what we’re looking at is patients with diabetes, and we are also including people without diabetes, but with heart failure.